News
Moon Shots Program
Since starting the Moon Shots Program™ in 2012, we’ve made progress. And lots of it. Keep checking back here to stay up-to-date on the program’s achievements and see our latest innovations.
/cancermoonshots/about/news.html
Lymphomas are the most common hematological malignancy in the U.S.,
accounting for an estimated 80,000 new cancer diagnoses and 21,000
deaths each year. These cancers, broadly classified as either Hodgkin
lymphomas or non-Hodgkin lymphomas, develop in the lymphatic system.
Approximately 85 percent of cases are B-cell lymphomas, meaning they
arise in B lymphocytes.
MD Anderson’s B-Cell Lymphoma Moon Shot™ is working toward...
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment...
The University of Texas MD Anderson Cancer Center applauds new actions announced today by the U.S. Food and Drug Administration (FDA) to limit...
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused...
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated...